glp 1 blood brain barrier The glucagon-like peptide (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action We keep learning more about
Description
Gala positions itself as an accessible option for patients who want GLP-1 therapy without the premium pricing charged by larger platforms
mRESVIA won approval based on the Phase III ConquerRSV trial, a global study of around 37,000 adults aged 60 or older in 22 countries, in which it displayed an efficacy rate of 83.7% against RSV lower respiratory tract disease
doi: 10.1183/16000617.0200-2021
During your consultation, the plastic surgeon will ask about your medical history and review any previous procedures you may have had
Given that GLP-1 and GIP receptor agonists are both having positive effects in PD models, researchers have recently developed a dual agonist that can cross the blood brain barrier (the protective membrane surrounding our brains)
The team sifted through more than 10,000 compounds via virtual screening to find out which ones bind to the receptor
